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ABSTRACT
Ovarian cancer is one of the neoplastic gynecological diseases that is the most difficult subject to screen-
ing. This is the reason that most newly-diagnosed cases are at III-IV FIGO stage. The lack of an appropriate 
screening method affects the oncologic results and, therefore, the ovarian cancer presents with the worst 
prognosis of all neoplasms of female reproductive organs. This review attempts to discuss some methods for 
early diagnosis of ovarian cancer, especially in cases with adnexial formation. The prognostic factors in the 
literature available influencing on patients’ survival and treatment outcomes are considered. 
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Peak incidence rate of the invasive epithelial 
ovarian carcinoma is at 56 and 60 years of age 
(6,30,35). This incidence increases steeply from 20 to 
80 years of age (30). Fewer than 1% of such cancers 
occur before the age of 21 years, and two-thirds of 
ovarian malignant tumours in this age are germ cell 
tumors (29,30,35). About 30% of ovarian neoplasms 
in postmenopausal women are malignant, whereas 
only about 7% of ovarian epithelial tumours in 
premenopausal patients are malignant (6,35). 
Ovarian carcinomas are associated with 
low parity and infertility (28). Early menarche 
and late menopause increase the risk of ovarian 
cancer (11). These facts and the relationship with 
parity and infertility have led to the hypothesis 
that suppression of ovulation may be an important 
factor. Theoretically, surface epithelium undergoes 
repetitive disruptions and repair. This process can 
lead to possible spontaneous mutations and the 
occurrence of oncogenic phenotype. 
The performance of prophylactic oophorectomy 
reduces, but does not completely eliminates the risk 
of ovarian cancer (31,38). As the entire peritoneum 
is at risk, peritoneal carcinomas can occur even after 
prophylactic oophorectomy. As the ovaries provide 
protection from cardiovascular and orthopedic 
diseases, the above mentioned intervention should 
not be routinely used in premenopausal women at 
low risk for ovarian cancer.
The value of tumour markers and ultrasound 
examination for screening of epithelial ovarian 
cancer is not clearly established by prospective 
studies. Screening results with transabdominal 
ultrasonography are encouraging (7,16,39), however, 
specificity is limited. The progress in transvaginal 
ultrasonography contributes to the very high 
sensitivity (95%) of the method for detection of 
ovarian cancer at an early stage, however,  the use 
of this test alone as a screening method allows a 
performance of 10-15 laparotomies for each case of 
detected cancer (7,16).
There are disappointing results from routine 
annual pelvic examination about the early detection 
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Genetic risk for epithelial ovarian carcinoma
The lifetime risk of ovarian cancer for women 
in the United States is about 1,4% (6,35).
The risk of ovarian cancer is higher in women 
with a certain family history compared with that of 
the general population. Most epithelial cancers are 
sporadic with familial or hereditary forms being 
5-10% of all malignant tumours. 
Hereditary ovarian cancer
Most hereditary ovarian carcinomas are 
associated with mutations in the BRCA1 gene located 
on chromosome 17. A small proportion of inherited 
disease is due to another gene, BRCA2, located on 
chromosome 13. These two genes are associated with 
genetic predisposition to both ovarian and breast 
cancer. 
Prevention 
As parity is inversely related to the risk of 
ovarian cancer, having at least one child has a 
protective effect on the disease and reducing the risk 
from 0,3 to 0,4. Oral contraceptive use reduces the 
risk of epithelial ovarian cancer (28). Women who use 
oral contraceptives for 5 or more years diminish their 
relative risk to 0,5 (50% reduction in the likelihood 
of development of ovarian cancer). Women with two 
children and oral contraceptive usage for 5 years or 
more present with 70% risk reduction (12). Therefore, 
the oral contraceptives are the only documented 
method of chemoprevention for ovarian cancer and 
it should be recommended for this purpose. This is 
important, especially in patients with family history 
of ovarian cancer.  
Fenretinide (4-hydroxyretinoic acid), a 
derivative of vitamin A, is given to women with 
unilateral breast cancer in an effort to reduce the 
risk of contralateral breast cancer. In a prospective, 
randomized, placebo-controlled study in Italy (9), 
fenretide or placebo are administered for 6 months 
in women with unilateral breast cancer. In the group 
with fenretinide, no ovarian cancer develops at all, 
whereas six cases are registered in the control group.
Prognostic factors
Treatment outcome can be assessed on the 
basis of prognostic factors which are divided into 
pathological, biological and clinical (23).
of ovarian cancer (33). Transvaginal colour-flow 
Doppler assessment of ovarian vessels is useful as a 
supplemental test to ultrasonography (24,25), but not 
for screening purposes. 
CA 125 has proven its role in the early diagnosis 
of epithelial ovarian cancer (10,18,19,34,39-41). CA 
125 can detect 50% of patients with stage I disease and 
60% of patients if those with stage II are included (34). 
CA125 specificity can be improved when combined 
with transvaginal ultrasonography (20) or if CA125 
levels are followed-up over time. These data enhance 
the implementation of prospective screening studies 
in Sweden and the United Kingdom (10,19). In them, 
patients with elevated CA125 levels (> 30 U/mL) 
have undergone abdominal ultrasonography and 14 
ovarian cancers are diagnosed among 27,000 women 
screened. About four laparotomies are performed for 
each case of cancer detected.  
In a randomized trial of 22,000 women 
aged 45 years or older in the UK (20), the patients 
are divided into a control group of routine pelvic 
examination (10,977) and a screening group (10,958). 
The screening consists of annual measurement 
of a serum CA125 levels, pelvic ultrasonography 
if the CA125 is 30 U/mL or higher, and referral to 
a gynecologist if the ovarian volume is 8,8 mM or 
greater on the ultrasonography. Of the 468 women 
from the screening group with an elevated CA125, 29 
are referred to a surgeon, six cancers are established, 
23 females present with a false-positive screening 
result, which means a positive predictive value of 
20,7%. During the 7-year follow-up period, cancer 
develops in 10 additional women from the screened 
group, as it does in 20 women from the control one. 
Although survival in women with cancer in the 
screened group is 72,9 months compared with 41,8 
months in the control one, mortality rate does not 
differ significantly between these groups (18/10977 
versus 9/10958; relative risk 2,00). Therefore, 
multimodal approach for screening of the ovarian 
cancer is feasible, however, a more comprehensive 
trial is needed to assess its effect on mortality.
Given the false-positive results for both CA125 
and transvaginal ultrasonography, particularly in 
premenopausal women these tests are not cost-
effective and should not be used routinely for 
screening purposes.
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Pathological factors
The morphological and histological patterns, 
including the architecture and grade of the lesion, are 
important prognostic variables (6). The histological 
type is of no prognostic value. However, it is recently 
suggested that clear-cell carcinomas are associated 
with a worse prognosis than other histological types 
(23,41). 
The histological grade determined by the 
degree of differentiation, the extent of the cellular 
anaplasia and the presence of undifferentiated cells 
are of prognostic significance. Because of the great 
subjectivism in grading estimation (1,15), however, 
its value as prognostic factor is not clearly established 
yet (23,41). Baak et al. (2) propose a standard 
grading system based on morphometric analysis 
that correlates with prognosis, especially due to 
its capacity to distinguish low-grade or borderline 
tumours from other neoplasms.
Biological factors
Several biological factors are associated with 
the prognosis of epithelial ovarian cancer. Using flow 
cytometry, it has been shown that ovarian cancers are 
aneuploidy (13) and there is a significant relationship 
between ploidy and FIGO stage. Early-staged cancers 
tend to be diploid while highly staged ones tend to be 
aneuploid (13,32). The patients with diploid tumours 
have a significantly longer median survival than 
those with aneuploid tumours of five years versus one 
year, respectively (13). Multivariate analysis shows 
that ploidy is an independent prognostic factor and 
one of the most important predictors of survival (13). 
More than 60 proto-oncogenes are already 
identified, and research focuses on amplification 
or expression of these genetic loci and their role in 
the development and progression of ovarian cancer 
(4,5). Some 30% of epithelial ovarian tumours 
express HER-2/neu oncogene and this group is of a 
poor prognosis, especially concerning the patients 
with more than five copies of the gene (37). A 
similar incidence rate (of 32%) of HER-2/neu gene 
expression is reported, too (3). The patients with such 
a gene expression have a shorter survival (15,7 versus 
32,8 months). Other authors do not confirm these 
findings (26,27). A literature review (26) reveals an 
overall incidence rate of HER-2/neu expression only 
about 11%. Thus the prognostic value of HER-2/neu 
expression in ovarian cancers remains unclear and 
requires further research.
p53 is the most commonly expressed tumour 
suppressor gene in ovarian carcinoma (14,17). 
Moreover, about half of all epithelial ovarian cancers 
have mutations in the p53 in the tumour.
Clinical factors
In addition to staging, the size of residual 
tumours after primary surgery, the volume of ascites, 
and patient’s age are independent prognostic factors 
(8,21,22,36,40). Among the patients with stage I 
disease, a multivariate analysis shows that grading 
and the dense adhesion of the tumour to the pelvic 
peritoneum exert a significant adverse effect on the 
prognosis, whereas intraoperative tumour spillage 
or rupture do not worsen the prognosis (8). Ovarian 
cancers that undergo intraoperative rupture or 
decomposition do not worsen the prognosis, whereas 
tumours ruptured preoperatively have a poorer 
prognosis (36). A multivariate analysis demonstrates 
that tumour grading, capsular penetration, surface 
growths and malignant ascites rather than any 
iatrogenic rupture are poor prognostic variables for 
early-stage ovarian cancers (40). 
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